Healthcare & Life Sciences

Synergia Medical

series-b
series-b
Stage
1
Investors

About

Synergia Medical develops an investigational optoelectronic neuromodulation implant (NAO.VNS) for vagus nerve stimulation that is designed to be MRI-compatible and immune to electromagnetic interference. The company has reported first-in-human implantations in Belgium as part of its AURORA clinical study.

Explore Synergia Medical's full profile on Brouky

Funding rounds, investor list, and risk signals — unlock with a subscription.